Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 94

1.

Analysis of the approach to risk management in onco-hematology centers: results of a survey in Italy.

Farina M, De Paoli G, Canciani M.

Tumori. 2016;102(Suppl 1):7-14. doi: 10.5301/tj.5000541. Epub 2016 Aug 29.

PMID:
27581595
2.

Evaluation of the Global Lung Initiative 2012 Reference Values for Spirometry in African Children.

Arigliani M, Canciani MC, Mottini G, Altomare M, Magnolato A, Loa Clemente SV, Tshilolo L, Cogo P, Quanjer PH.

Am J Respir Crit Care Med. 2017 Jan 15;195(2):229-236. doi: 10.1164/rccm.201604-0693OC.

PMID:
27564235
3.

Administrative risk quantification of subcutaneous and intravenous therapies in Italian centers utilizing the Failure Mode and Effects Analysis approach.

Ponzetti C, Canciani M, Farina M, Era S, Walzer S.

Clinicoecon Outcomes Res. 2016 Aug 3;8:353-9. doi: 10.2147/CEOR.S97323. eCollection 2016.

5.

Resource And Cost Savings Due To Subcutaneous Versus Intravenous Administration Of Oncology Therapies: Case Studies With Rituximab (Mabthera) And Trastuzumab (Herceptin).

Walzer S, Era S, Profico A, Canciani M, Farina M, Ponzetti C.

Value Health. 2015 Nov;18(7):A466. doi: 10.1016/j.jval.2015.09.1220. Epub 2015 Oct 20. No abstract available.

6.

Safety And Insurance Premium Implications For Hospitals Based On Subcutaneous Versus Intravenous Administration Of Oncology / Hematology Therapies: Case Studies With Rituximab (Mabthera) And Trastuzumab (Herceptin).

Walzer S, Era S, Profico A, Canciani M, Farina M, Ponzetti C.

Value Health. 2015 Nov;18(7):A440. doi: 10.1016/j.jval.2015.09.1075. Epub 2015 Oct 20. No abstract available.

7.

Predictors of von Willebrand disease diagnosis in individuals with borderline von Willebrand factor plasma levels.

Bucciarelli P, Siboni SM, Stufano F, Biguzzi E, Canciani MT, Baronciani L, Pagliari MT, La Marca S, Mistretta C, Rosendaal FR, Peyvandi F.

J Thromb Haemost. 2015 Feb;13(2):228-36. doi: 10.1111/jth.12799. Epub 2015 Jan 9.

8.

Organizational and Management Impact Analysis of Using the New Subcutaneous Formulation of Tocilizumab in Selected Italian Rheumatology Centers.

Ravera S, Tomic R, Adami S, Viapiana O, Paolini D, Bianchino L, Canciani M, Farina M, Ciancio G, Govoni M.

Value Health. 2014 Nov;17(7):A383. doi: 10.1016/j.jval.2014.08.2632. Epub 2014 Oct 26. No abstract available.

9.

Efficacy of Grintuss® pediatric syrup in treating cough in children: a randomized, multicenter, double blind, placebo-controlled clinical trial.

Canciani M, Murgia V, Caimmi D, Anapurapu S, Licari A, Marseglia GL.

Ital J Pediatr. 2014 Jun 10;40:56. doi: 10.1186/1824-7288-40-56.

10.

Hyponatremia in radiologically confirmed pediatric community-acquired pneumonia.

Don M, Valerio G, Canciani M, Korppi M.

Pediatr Emerg Care. 2014 Jan;30(1):76. doi: 10.1097/PEC.0000000000000039. No abstract available.

PMID:
24378869
11.

A synonymous (c.3390C>T) or a splice-site (c.3380-2A>G) mutation causes exon 26 skipping in four patients with von Willebrand disease (2A/IIE).

Pagliari MT, Baronciani L, Garcìa Oya I, Solimando M, La Marca S, Cozzi G, Stufano F, Canciani MT, Peyvandi F.

J Thromb Haemost. 2013 Jul;11(7):1251-9. doi: 10.1111/jth.12280.

12.

VWF propeptide and ratios between VWF, VWF propeptide, and FVIII in the characterization of type 1 von Willebrand disease.

Eikenboom J, Federici AB, Dirven RJ, Castaman G, Rodeghiero F, Budde U, Schneppenheim R, Batlle J, Canciani MT, Goudemand J, Peake I, Goodeve A; MCMDM-1VWD Study Group.

Blood. 2013 Mar 21;121(12):2336-9. doi: 10.1182/blood-2012-09-455089. Epub 2013 Jan 24.

13.

A comparative evaluation of a new automated assay for von Willebrand factor activity.

Lawrie AS, Stufano F, Canciani MT, Mackie IJ, Machin SJ, Peyvandi F.

Haemophilia. 2013 Mar;19(2):338-42. doi: 10.1111/hae.12064. Epub 2012 Dec 4.

14.

Molecular characterization, recombinant protein expression, and mRNA analysis of type 3 von Willebrand disease: Studies of an Italian cohort of 10 patients.

Solimando M, Baronciani L, La Marca S, Cozzi G, Asselta R, Canciani MT, Federici AB, Peyvandi F.

Am J Hematol. 2012 Sep;87(9):870-4. doi: 10.1002/ajh.23265. Epub 2012 Jun 5.

15.

Total viable molds and fungal DNA in classrooms and association with respiratory health and pulmonary function of European schoolchildren.

Simoni M, Cai GH, Norback D, Annesi-Maesano I, Lavaud F, Sigsgaard T, Wieslander G, Nystad W, Canciani M, Viegi G, Sestini P.

Pediatr Allergy Immunol. 2011 Dec;22(8):843-52. doi: 10.1111/j.1399-3038.2011.01208.x.

PMID:
22122789
16.

Management of inherited von Willebrand disease in Italy: results from the retrospective study on 1234 patients.

Federici AB, Bucciarelli P, Castaman G, Baronciani L, Canciani MT, Mazzucconi MG, Morfini M, Rocino A, Schiavoni M, Oliovecchio E, Iorio A, Mannucci PM.

Semin Thromb Hemost. 2011 Jul;37(5):511-21. doi: 10.1055/s-0031-1281037. Epub 2011 Nov 18.

17.

Platelet reactive conformation and multimeric pattern of von Willebrand factor in acquired thrombotic thrombocytopenic purpura during acute disease and remission.

Lotta LA, Lombardi R, Mariani M, Lancellotti S, De Cristofaro R, Hollestelle MJ, Canciani MT, Mannucci PM, Peyvandi F.

J Thromb Haemost. 2011 Sep;9(9):1744-51. doi: 10.1111/j.1538-7836.2011.04428.x.

18.

Radiological and etiological aspects of severe pediatric pneumococcal community-acquired pneumonia.

Don M, Canciani M.

Pediatr Pulmonol. 2011 Aug;46(8):829-30; author reply 831. doi: 10.1002/ppul.21439. Epub 2011 Apr 12. No abstract available.

PMID:
21491615
19.

The effect of prion reduction in solvent/detergent-treated plasma on haemostatic variables.

Lawrie AS, Green L, Canciani MT, Mackie IJ, Peyvandi F, Scully MA, Machin SJ.

Vox Sang. 2010 Oct;99(3):232-8. doi: 10.1111/j.1423-0410.2010.01346.x.

PMID:
20840338
20.

Prediction of delayed recovery from pediatric community-acquired pneumonia.

Don M, Valent F, Canciani M, Korppi M.

Ital J Pediatr. 2010 Jul 29;36:51. doi: 10.1186/1824-7288-36-51.

21.

Community-acquired pneumonia in children: what's old? What's new?

Don M, Canciani M, Korppi M.

Acta Paediatr. 2010 Nov;99(11):1602-8. doi: 10.1111/j.1651-2227.2010.01924.x. Epub 2010 Jul 13. Review.

PMID:
20573146
22.

School air quality related to dry cough, rhinitis and nasal patency in children.

Simoni M, Annesi-Maesano I, Sigsgaard T, Norback D, Wieslander G, Nystad W, Canciani M, Sestini P, Viegi G.

Eur Respir J. 2010 Apr;35(4):742-9. doi: 10.1183/09031936.00016309. Epub 2010 Jan 14.

23.

Serologically verified human bocavirus pneumonia in children.

Don M, Söderlund-Venermo M, Valent F, Lahtinen A, Hedman L, Canciani M, Hedman K, Korppi M.

Pediatr Pulmonol. 2010 Feb;45(2):120-6. doi: 10.1002/ppul.21151.

PMID:
19960524
24.

Relevance of chloride binding to von Willebrand factor in type 2B von Willebrand disease patients.

Baronciani L, Peyvandi F, Punzo M, Lancellotti S, Canciani MT, Federici AB, de Cristofaro R.

J Thromb Haemost. 2010 Feb;8(2):416-8. doi: 10.1111/j.1538-7836.2009.03706.x. Epub 2009 Nov 26. No abstract available.

25.

Transient hemi-diaphragmatic palsy following pleural empyema: a pediatric case report.

Don M, Russo V, Budai R, Canciani M.

Pediatr Med Chir. 2009 Jul-Aug;31(4):172-5.

PMID:
19839401
26.

Type 2A (IIH) von Willebrand disease is due to mutations that affect von Willebrand factor multimerization.

Baronciani L, Federici AB, Punzo M, Solimando M, Cozzi G, La Marca S, Rubini V, Canciani MT, Mannucci PM.

J Thromb Haemost. 2009 Jul;7(7):1114-22. doi: 10.1111/j.1538-7836.2009.03457.x. Epub 2009 Apr 24.

27.

Clinical and laboratory versus molecular markers for a correct classification of von Willebrand disease.

Federici AB, Canciani MT.

Haematologica. 2009 May;94(5):610-5. doi: 10.3324/haematol.2009.005751.

28.

Differentiation of bacterial and viral community-acquired pneumonia in children.

Don M, Valent F, Korppi M, Canciani M.

Pediatr Int. 2009 Feb;51(1):91-6. doi: 10.1111/j.1442-200X.2008.02678.x.

PMID:
19371285
29.

Clinical and molecular predictors of thrombocytopenia and risk of bleeding in patients with von Willebrand disease type 2B: a cohort study of 67 patients.

Federici AB, Mannucci PM, Castaman G, Baronciani L, Bucciarelli P, Canciani MT, Pecci A, Lenting PJ, De Groot PG.

Blood. 2009 Jan 15;113(3):526-34. doi: 10.1182/blood-2008-04-152280. Epub 2008 Sep 19.

30.

Hyper- and hypoglycemia in children with community-acquired pneumonia.

Don M, Valerio G, Korppi M, Canciani M.

J Pediatr Endocrinol Metab. 2008 Jul;21(7):657-64.

PMID:
18780600
31.

Second international collaborative study evaluating performance characteristics of methods measuring the von Willebrand factor cleaving protease (ADAMTS-13).

Tripodi A, Peyvandi F, Chantarangkul V, Palla R, Afrasiabi A, Canciani MT, Chung DW, Ferrari S, Fujimura Y, Karimi M, Kokame K, Kremer Hovinga JA, Lämmle B, de Meyer SF, Plaimauer B, Vanhoorelbeke K, Varadi K, Mannucci PM.

J Thromb Haemost. 2008 Sep;6(9):1534-41. doi: 10.1111/j.1538-7836.2008.03099.x. Epub 2008 Jul 26.

32.

Human metapneumovirus pneumonia in children: results of an Italian study and mini-review.

Don M, Korppi M, Valent F, Vainionpaa R, Canciani M.

Scand J Infect Dis. 2008;40(10):821-6. doi: 10.1080/00365540802227110. Review.

PMID:
18618373
33.

Hyponatremia in pediatric community-acquired pneumonia.

Don M, Valerio G, Korppi M, Canciani M.

Pediatr Nephrol. 2008 Dec;23(12):2247-53. doi: 10.1007/s00467-008-0910-2. Epub 2008 Jul 8.

PMID:
18607640
34.

The value of clinical features in differentiating between viral, pneumococcal and atypical bacterial pneumonia in children.

Korppi M, Don M, Valent F, Canciani M.

Acta Paediatr. 2008 Jul;97(7):943-7. doi: 10.1111/j.1651-2227.2008.00789.x. Epub 2008 Apr 15.

PMID:
18422803
35.

Clinical and laboratory findings in the diagnosis of bacterial pneumonia in children.

Don M, Canciani M, Valent F, Korppi M.

Swiss Med Wkly. 2008 Mar 8;138(9-10):151; author reply 151. doi: 2008/09/smw-11935. No abstract available.

PMID:
18330736
36.

Expression studies of missense mutations p.D141Y, p.C275S located in the propeptide of von Willebrand factor in patients with type 3 von Willebrand disease.

Baronciani L, Federici AB, Cozzi G, La Marca S, Punzo M, Rubini V, Canciani MT, Mannucci PM.

Haemophilia. 2008 May;14(3):549-55. doi: 10.1111/j.1365-2516.2008.01682.x. Epub 2008 Mar 4.

PMID:
18328061
37.

ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission.

Peyvandi F, Lavoretano S, Palla R, Feys HB, Vanhoorelbeke K, Battaglioli T, Valsecchi C, Canciani MT, Fabris F, Zver S, Réti M, Mikovic D, Karimi M, Giuffrida G, Laurenti L, Mannucci PM.

Haematologica. 2008 Feb;93(2):232-9. doi: 10.3324/haematol.11739. Epub 2008 Jan 26.

38.

Simkania negevensis in community-acquired pneumonia in Italian children.

Fasoli L, Paldanius M, Don M, Valent F, Vetrugno L, Korppi M, Canciani M.

Scand J Infect Dis. 2008;40(3):269-72. Epub 2007 Sep 28.

PMID:
17907044
39.

ADAMTS13 activity to antigen ratio in physiological and pathological conditions associated with an increased risk of thrombosis.

Feys HB, Canciani MT, Peyvandi F, Deckmyn H, Vanhoorelbeke K, Mannucci PM.

Br J Haematol. 2007 Aug;138(4):534-40. Epub 2007 Jun 29.

PMID:
17608762
40.

Evaluation of a new turbidimetric assay for von Willebrand factor activity useful in the general screening of von Willebrand disease.

Piñol M, Sales M, Costa M, Tosetto A, Canciani MT, Federici AB.

Haematologica. 2007 May;92(5):712-3.

41.

Efficacy of serum procalcitonin in evaluating severity of community-acquired pneumonia in childhood.

Don M, Valent F, Korppi M, Falleti E, De Candia A, Fasoli L, Tenore A, Canciani M.

Scand J Infect Dis. 2007;39(2):129-37.

PMID:
17366029
42.

Recurrent respiratory infections and phagocytosis in childhood.

Don M, Fasoli L, Gregorutti V, Pisa F, Valent F, Prodan M, Canciani M.

Pediatr Int. 2007 Feb;49(1):40-7.

PMID:
17250504
43.
44.

von Willebrand factor collagen binding assay in von Willebrand disease type 2A, 2B, and 2M.

Baronciani L, Federici AB, Cozzi G, Canciani MT, Mannucci PM.

J Thromb Haemost. 2006 Sep;4(9):2088-90. No abstract available.

45.

The thrombospondin-1 N700S polymorphism is associated with early myocardial infarction without altering von Willebrand factor multimer size.

Zwicker JI, Peyvandi F, Palla R, Lombardi R, Canciani MT, Cairo A, Ardissino D, Bernardinelli L, Bauer KA, Lawler J, Mannucci P.

Blood. 2006 Aug 15;108(4):1280-3. Epub 2006 May 9.

46.

Simkania negevensis and pneumonia in children.

Don M, Paldanius M, Fasoli L, Canciani M, Korppi M.

Pediatr Infect Dis J. 2006 May;25(5):470-1; author reply 471-2. No abstract available.

PMID:
16645522
47.

An association of candidate gene haplotypes and bleeding severity in von Willebrand disease type 2A, 2B, and 2M pedigrees.

Kunicki TJ, Baronciani L, Canciani MT, Gianniello F, Head SR, Mondala TS, Salomon DR, Federici AB.

J Thromb Haemost. 2006 Jan;4(1):137-47.

48.

Aetiology of community-acquired pneumonia: serological results of a paediatric survey.

Don M, Fasoli L, Paldanius M, Vainionpää R, Kleemola M, Räty R, Leinonen M, Korppi M, Tenore A, Canciani M.

Scand J Infect Dis. 2005;37(11-12):806-12.

PMID:
16308213
49.

Expression studies on a novel type 2B variant of the von Willebrand factor gene (R1308L) characterized by defective collagen binding.

Baronciani L, Federici AB, Beretta M, Cozzi G, Canciani MT, Mannucci PM.

J Thromb Haemost. 2005 Dec;3(12):2689-94. Epub 2005 Oct 25.

50.

Opposite changes of ADAMTS-13 and von Willebrand factor after cardiac surgery.

Mannucci PM, Parolari A, Canciani MT, Alemanni F, Camera M.

J Thromb Haemost. 2005 Feb;3(2):397-9. No abstract available.

Supplemental Content

Loading ...
Support Center